Business Context and Reporting Period
This Form 8-K is a current report filed by Nuvilex, Inc. (noted in metadata as Pharmacyte Biotech, Inc.) on March 8, 2010. The registrant is incorporated in Nevada with principal executive offices in Cherry Hill, New Jersey. The filing addresses a change in the company's certifying accountant.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the administrative change of the independent auditor.
Material Changes
- Dismissal of Auditor: On March 8, 2010, the Board of Directors approved the dismissal of Gruber & Company, LLC as the independent auditor.
- Engagement of New Auditor: On the same date, the company engaged M & K CPAS, PLLC to audit financial statements and perform interim reviews.
- Audit History: Reports by the former auditor for fiscal years ended April 30, 2009, and 2008 contained no adverse opinions, disclaimers, or qualifications regarding uncertainty, scope, or accounting principles.
- No Disagreements: The company reported no disagreements with the former auditor on accounting principles, practices, or disclosures, and no "reportable events" occurred during the relevant periods.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding business outlook, financial guidance, or specific operational risks. It confirms that no consultations occurred with the new auditor regarding accounting principles or potential audit opinions prior to their engagement.
Investor Verification Checklist
- Verify the reason for the auditor change, as the filing states no disagreements or reportable events occurred.
- Confirm the identity of the new auditor, M & K CPAS, PLLC, and their qualifications.
- Review the most recent audited financial statements (fiscal years ended April 30, 2009 and 2008) to assess the company's financial health, as this 8-K does not contain financial data.
- Check for any subsequent filings that may provide details on the transition between accounting firms.